• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Auven Therapeutics, Mount Sinai ink license agreement for sarcoidosis

Auven Therapeutics, Mount Sinai ink license agreement for sarcoidosis

May 5, 2014
CenterWatch Staff

Auven Therapeutics, a global private equity company focused on accelerated development of breakthrough therapeutic drugs, has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which Auven obtains rights to develop KIACTA (eprodisate) as a treatment for chronic sarcoidosis.

Auven intends to conduct a phase II (proof-of-concept) clinical trial to evaluate KIACTA’s effectiveness and safety to treat certain medical manifestations of sarcoidosis. KIACTA is aimed at addressing the disease process (i.e. pathophysiology) in sarcoidosis patients. Auven expects to finalize a study protocol by mid-year and anticipates the trial will begin dosing patients in the fourth quarter of 2014. The phase II trial is expected to be completed within approximately 18 months after the first patient is enrolled.

The idea to use KIACTA as a treatment for chronic sarcoidosis was developed by Adam S. Morgenthau, M.D., assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai. Morgenthau is the director of the Sarcoidosis Clinic at Mount Sinai, which specializes in treating patients with complex cases.

Sarcoidosis is a rare condition that causes small patches of red and swollen tissue—called granulomas—that can develop in multiple organs in the body, but mostly in the lungs and skin. The disease affects approximately 20,000 patients in the U.S. alone and identification of an effective treatment is a major unmet medical need. While acute sarcoidosis can improve on its own, chronic sarcoidosis can cause scarring to the lungs and decreased lung function over time, potentially affecting other areas of the body, including the liver.

“There is no cure for sarcoidosis, and treatment options are limited and can have serious adverse effects,” said Peter B. Corr, co-founder and managing general partner of Auven Therapeutics.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing